Table 1

Glycemia at 3 and 9 months’ diabetes duration

Prevention studyIntervention study
Experimental groupFasting blood glucose,
3 months’ durationGlycohemoglobin,
9 months’ durationFasting blood glucose,
3 months’ durationGlycohemoglobin,
9 months’ duration
Nondiabetic166 ± 20 (9.2 ± 1.1)3.0 ± 0.13 (9 ± 1.4)172 ± 22 (9.5 ± 1.2)3.8 ± 0.09 (17 ± 1)
SD458 ± 51 (25 ± 2.8)*10.9 ± 0.81 (95 ± 8.9)*472 ± 46 (26.2 ± 2.5)*11.6 ± 0.71 (95 ± 9.2)*
SD + montelukast/water476 ± 41 (26 ± 2.3)*11.1 ± 0.81 (98 ± 8.9)*512 ± 50 (28.4 ± 2.8)*10.9 ± 0.84 (102 ± 78)*
SD + montelukast/IP466 ± 66 (26 ± 3.6)*
SD + montelukast/oral417 ± 57 (23 ± 3.2)*
  • Data are presented as the average ± SD mg/dL (mmol/L). IP, intraperitoneal; SD, streptozotocin diabetic.

  • *P < 0.05 compared with nondiabetic mice.